Synlogic

Synlogic is a clinical-stage biotechnology company that applies synthetic biology to engineer beneficial gut bacteria, primarily probiotic E. coli Nissle, into 'Synthetic Biotics' — living medicines designed to sense and respond to disease signals inside the body. Its oral, non-systemically absorbed biotherapeutics target metabolic and immune conditions where the engineered microbes perform or deliver functions patients' own bodies cannot. Synlogic is publicly traded and works with academic and pharmaceutical partners to advance its pipeline of synthetic biotic candidates toward clinical care.